Targeted immunomodulation using antigen-conjugated nanoparticles

ABSTRACT The growing prevalence of nanotechnology in the fields of biology, medicine, and the pharmaceutical industry is confounded by the relatively small amount of data on the impact of these materials on the immune system. In addition to concerns surrounding the potential toxicity of nanoparticle...

Full description

Saved in:
Bibliographic Details
Published in:Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Vol. 6; no. 3; pp. 298 - 315
Main Authors: McCarthy, Derrick P., Hunter, Zoe N., Chackerian, Bryce, Shea, Lonnie D., Miller, Stephen D.
Format: Journal Article
Language:English
Published: Hoboken, USA John Wiley & Sons, Inc 01-05-2014
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT The growing prevalence of nanotechnology in the fields of biology, medicine, and the pharmaceutical industry is confounded by the relatively small amount of data on the impact of these materials on the immune system. In addition to concerns surrounding the potential toxicity of nanoparticle (NP)‐based delivery systems, there is also a demand for a better understanding of the mechanisms governing interactions of NPs with the immune system. Nanoparticles can be tailored to suppress, enhance, or subvert recognition by the immune system. This ‘targeted immunomodulation’ can be achieved by delivery of unmodified particles, or by modifying particles to deliver drugs, proteins/peptides, or genes to a specific site. In order to elicit the desired, beneficial immune response, considerations should be made at every step of the design process: the NP platform itself, ligands, and other modifiers, the delivery route, and the immune cells that will encounter the conjugated NPs can all impact host immune responses. This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease
Bibliography:istex:66C4B20CCDF4FBF8BCDB3C5DC68E92AD892B331E
Myelin Repair Foundation
National Multiple Sclerosis Society
ark:/67375/WNG-29Q4K71F-V
ArticleID:WNAN1263
Juvenile Diabetes Research Foundation
National Institutes of Health
Conflict of interest: The authors have declared no conflicts of interest for this article.
Authors contributed equally
ISSN:1939-5116
1939-0041
DOI:10.1002/wnan.1263